

DAFTAR PUSTAKA

- Aggarwal A, Aggarwal S, Sarkar PG, Sharma V. Predisposing factors to premature coronary artery disease in young (age \leq 45 years) smokers: a single center retrospective case control study from India. *J Cardiovasc Thorac Res* 2014;6: 15-19.
- Aggarwal A, Srivastava S, Velmurugan M. Newer perspectives of coronary artery disease in young. *World J Cardiol* 2016;8(12):728-734.
- Alexander RW. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: A new perspective. *Hypertension* 1995;25(2):155-161.
- Alkorashy M, Ramji DP. Anti-inflammatory actions of statins in human macrophages. *Atherosclerosis* 2014;235(2):e266
- Anderson DR, Poterucha JT, Mikuls TR, et al. IL-6 and its receptors in coronary artery disease and acute myocardial infarction. *Cytokine* 2013;62:395–400.
- Andresdottir MB, Sigurdsson G, Sigvaldason H, Gudnason V; Reykjavik Cohort Study. Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study. *Eur Heart J* 2002;23(21):1655-1663.
- Anna A, Monika G. Splicing mutations in human genetic disorders: examples, detection, and confirmation. *Journal of Applied Genetics* 2018;59:253–268.
- Askevold ET, Nymo S, Ueland T, et al. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). *Circulation: Heart Failure* 2013;6:91–98.
- Bacchiega BC, Bacchiega AB, Usnayo MJ, Bedirian R, Singh G, Pinheiro GD. Interleukin 6 inhibition and coronary artery disease in a high-risk population: A prospective community-based clinical study. *J Am Heart Assoc* 2017;6(3):e005038. Published 2017 Mar 13. doi:10.1161/JAHA.116.005038.

- Bahrami H, Budoff M, Haberlen SA, et al. Inflammatory markers associated with subclinical coronary artery disease: The Multicenter AIDS Cohort Study. *J Am Heart Assoc* 2016;5:e003371 doi: 10.1161/JAHA.116.003371.
- Barkhausen T, Tschernig T, Rosenstiel P, et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. *Critical Care Medicine* 2011;39:1407–1413.
- Benrick A, Jirholt P, Wernstedt I, et al. A non-conservative polymorphism in the IL-6 signal transducer (IL6ST)/gp130 is associated with myocardial infarction in a hypertensive population. *Regulatory Peptides* 2008;146:189–196.
- Boekholdt SM, Stores ESG. The interleukin-6 pathway and atherosclerosis. *The Lancet* 2012;379:1176-1178.
- Bonomi A, Veglia F, Baldassarre D, et al. Novel genetic variants associated with circulating soluble glycoprotein 130 levels in the IMPROVE study. *Circulation*. 2017;136:A20011.
- C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. *BMJ* 2011;342:d548– d558.
- Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. *Nature Reviews Rheumatology* 2014;10:720-724.
- Campbell IL, Erta M, Lim SL, et al. Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. *The Journal of Neuroscience* 2014;34:2503–2513.
- Chase KA, Cone JJ, Rosen C, Sharma RP. The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia. *BMC Psychiatry* 2016;16(152):7 pages.
- Chen Z, Qian Q, Tang CC, Ding JD, Feng Y, Ma GS. Association of two variants in the interleukin-6 receptor gene and premature coronary heart disease in a Chinese Han population. *Molecular Biology Reports* 2013;40(2):1021–1026.
- Cojocaru IM, Cojocaru M, Miu G, Sapira V. Study of interleukin-6 production in Alzheimer's disease. *Rom J Intern Med* 2011;49(1):55-58.

- Cole JH, Miller JI 3rd, Sperling LS, Weintraub WS. Long-term follow-up of coronary artery disease presenting in young adults. *J Am Coll Cardiol* 2003;41(4):521-528.
- Crit Rev Eukaryot Gene Expr. 2017;27(3):229-236. doi: 10.1615/CritRevEukaryotGeneExpr.2017019712.
- Cui YX, Fu CW, Jiang F, Ye LX, Meng W. Association of the interleukin-6 polymorphisms with systemic lupus erythematosus: a meta-analysis. *Lupus* 2015;24(12):1308–1317.
- Elliott P, Chambers JC, Zhang W, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. *The Journal of the American Medical Association* 2009;302:37–48.
- El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. *Oncologist* 2011;16(4):497-511.
- Ferreira RC, Freitag DF, Cutler AJ, et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. *PLoS Genet* 2013;9(4):e1003444.
- Fotis L, Agrogiannis G, Vlachos IS, et al. Intercellular Adhesion Molecule (ICAM)-1 and Vascular Cell Adhesion Molecule (VCAM)-1 at the Early Stages of Atherosclerosis in a Rat Model. *In Vivo*. 2012;26:243-250.
- Furukawa Y, Ehara N, Taniguchi R, et al; CREDO-Kyoto Investigators. Coronary risk factor profile and prognostic factors for young Japanese patients undergoing coronary revascularization. *Circ J* 2009;73(8):1459-1465.
- Fuster JJ, Walsh K. The good, the bad, and the ugly of interleukin-6 signaling. *The EMBO Journal* 2014;33:1425–1427.
- Gabay C. Interleukin 6 and chronic inflammation. *Arthritis Research and Therapy* 2006;8:S3
- Galicia JC, Tai H, Komatsu Y, et al. Polymorphisms in the IL-6 receptor (IL-6r) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. *Genes Immun* 2004;5:513–516.
- Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. *Current Opinion in Immunology* 2015;34:75–82.
- Garbers C, Monhasery N, Aparicio-Siegmund S, et al. The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased

proteolytic conversion rates by ADAM proteases. *Biochimica et Biophysica Acta* 2014;1842:1485–1494.

Garbers C, Thaiss W, Jones GW, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. *The Journal of Biological Chemistry* 2011;286(50):42959–42970.

Gross MD, Bielinski SJ, Suarez-Lopez JR, et al. Circulating soluble intercellular adhesion molecule 1 and subclinical atherosclerosis: the coronary artery risk development in young adults study. *Clinical Chemistry* 2012;58(2):411–420.

Harrison SC, Smith AJ, Jones GT, et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. *Eur Heart J* 2013;34(48):3707–3716.

Hartman J, Frishman WH. Inflammation and atherosclerosis: A review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. *Cardiology in Review* 2014;22:147–151.

Hawkins GA, Robinson MB, Hastie AT, et al. IL6R Variation Asp358Ala is a potential modifier of lung function in asthma. *J Allergy Clin Immunol* 2012;130:510–515.

He F, Teng X, Gu H, et al. Interleukin-6 receptor rs7529229 T/C polymorphism is associated with left main coronary artery disease phenotype in a Chinese population. *Int J Mol Sci* 2014;15:5623–5633.

Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. *Biochem J* 2003;374:1–20.

Hoge J, Yan I, Janner N, et al. IL-6 controls the innate immune response against *Listeria monocytogenes* via classical IL-6 signaling. *The Journal of Immunology* 2013;190:703–711.

Hongmei Y, Yongping J, Jiyuan L. Interleukin-6 polymorphisms and risk of coronary artery diseases in a Chinese population: A case-control study. *Pak J Med Sci.* 2016;32(4):880–885.

Hou T, Tieu BC, Ray S, Recinos Iii A, Cui R, Tilton RG, Brasier AR. Roles of IL-6-gp130 signaling in vascular inflammation. *Curr Cardiol Rev.* 2008;4:179–192.

Hussain MA, Mamun AA, Peters SAE, et al. The burden of cardiovascular disease attributable to major modifiable risk factors in Indonesia. *J Epidemiol* 2016;26:515–521.

- Inoue S, Zimmet P, Caterson I, et al. The Asia-Pacific perspective: Redefining obesity and its treatment. Health Communication Australia 2000.
- Jawień J. Atherosclerosis in 2012: What is new? *Pol Arch Med Wewn* 2012;122:170-173.
- Jayedi A, Rahimi K, Bautista LE, et al. Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies. *Heart* 2019;105:686-692.
- Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 transsignaling: the in vivo consequences. *J Interferon Cytokine Res.* 2005;25:241–253.
- Jostock T, Mullberg J, Ozbek S, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. *Eur J Biochem* 2001;268:160-167.
- Kam R, Cutter J, Chew SK, et al. Gender differences in outcome after an acute myocardial infarction in Singapore. *Singapore Med J* 2002;43(5):243-248.
- Kaptoge S, Di Angelantonio E, et al. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. *The Lancet* 2010;375:132-140.
- Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. *Vitam Horm* 2009;80:613-633.
- Kim JH, Jeong MH. Can family history of premature coronary artery disease be a risk factor for clinical outcomes in patients with acute myocardial infarction? *Korean J Intern Med* 2013;28:538-540.
- Kim L, Lee H, Kim Y, et al. Identification of novel SNPs in the interleukin 6 receptor gene (IL6R). *Hum Mut* 2003;21(4):450–451.
- Kishimoto T. IL-6: from its discovery to clinical applications. *International Immunology* 2010;22:347–352.
- Kraakman MJ, Kammoun HL, Allen TL, et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. *Cell Metabolism* 2015;21:403–416.
- Kristiansen OP, Poulsen TM1. Interleukin-6 and diabetes. The good, the bad, or the indifferent? *Diabetes* 2005;54(2):S114-S124.
- Kunutsor SK, Laukkanen JA. Should inflammatory pathways be targeted for the prevention and treatment of hypertension? *Heart* 2019;105:665-667.

- Libby P. Inflammation in atherosclerosis. *Arterioscler Thromb Vasc Biol* 2012;32:2045-2051.
- Lubrano V, Balzan S. Consolidated and emerging inflammatory markers in coronary artery disease. *World J Exp Med* 2015;5(1):21-32.
- Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. *Arterioscler Thromb Vasc Biol* 2003;23:1255–1261.
- Luedde M, Schaefer AS, Scheller N, et al. Key genes of the interleukin 6 signaling pathway are not associated with coronary artery disease in a large European population. *Open Journal of Genetics* 2013;3:67-78.
- Luig M, Kluger MA, Goerke B, et al. Inflammation-induced IL-6 functions as a natural brake on macrophages and limits GN. *Journal of the American Society of Nephrology* 2015;26:1597–1607.
- Madan M, Bishayi B, Hoge M, Amar S. Atheroprotective role of interleukin-6 in diet- and/or pathogen-associated atherosclerosis using an ApoE heterozygote murine model. *Atherosclerosis* 2008;197:504–514.
- Madiyono B, Moeslichan SM, Sastroasmoro S, et al.. Perkiraan besar sampel. Dalam: Sastroasmoro S, Ismael S. *Dasar-dasar metodologi penelitian klinis*. Ed. 4. Sagung Seto 2011:359-360.
- Matsumoto S, Hara T, Mitsuyama K et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. *Journal of Immunology* 2010;184:1543–1551.
- Mauer J, Chaurasia B, Goldau J, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. *Nature Immunology* 2014;15:423–430.
- Ministry of Health New Zealand. Cardiovascular disease risk assessment and management for primary care. Wellington 2018.
- Moreno VI, Golabkesh Z, Kallberg H, et al. Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction. *Atherosclerosis* 2015;240:477-481.
- Morieri ML, Passaro A, Zuliani G. Interleukin-6 trans-signaling and ischemic vascular disease: The important role of soluble gp130. *Mediators of*

Inflammation 2017; Article ID 1396398:6 pages.
doi:10.1155/2017/1396398.

Murray PJ. The JAK-STAT signaling pathway: input and output integration. *J Immunol* 2007;178:2623-2629.

Murugan M, Ramalingam K, Nazzuredin M, et al. SNP's and its correlation with hypertension: A comprehensive review. *Dentistry and Medical Research* 2013;1(1):3-6.

Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). *BJU Int* 2014;113(6):986-992.

Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. *Ann Intern Med.* 2003;139:761-776.

Otaki Y, Gransar H, Berman DS, et al. Impact of family history of coronary artery disease in young individuals (from the CONFIRM registry). *Am J Cardiol* 2013;111:1081-1086.

Ozougwu J C, Obimba KC, Belonwu CD, Unakalamba CB. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. *Journal of Physiology and Pathophysiology* 2013;4(4):46-57.

Pan HC, Sheu WHH, Lee WJ, et al. Coronary severity score and C-reactive protein predict major adverse cardiovascular events in patients with stable coronary artery disease (from the Taichung CAD study). *Clinica Chimica Acta* 2015;445:93-100.

Park JW, Chang JH, Park SH, et al. Interleukin-6 is associated with obesity, central fat distribution, and disease severity in patients with acute pancreatitis. *Pancreatology* 2015;15(1):59-63.

Puranik R, Fox OJ, Sullivan DS, et al. Inflammatory characteristics of premature coronary artery disease. *International Journal of Cardiology* 2010;145(2):288-290.

Ramos TN, Bullard DC, Barnum SR. ICAM-1: Isoforms and phenotypes. *J Immunol* 2014;192:4469-4474.

Ramsay SA, Gold ES, Aderem A. A systems biology approach to understanding atherosclerosis. *Embo Molecular Medicine* 2010;2:79-89.

Rehman K, Akash MSH, Liaqat A, Kamal S, Qadir MI, Rasul A. Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus. *Crit Rev Eukaryot Gene Expr* 2017;27(3):229-236.

- Reiss AB, Siegart NM, De Leon J. Interleukin-6 in atherosclerosis: atherogenic or atheroprotective? *Clinical Lipidology* 2017;12(1):14-23.
- Revez J, Bain L, Chapman B, et al. A new regulatory variant in the interleukin-6 receptor gene associates with asthma risk. *Genes and Immunity* 2013;14:441-446.
- Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. *International Journal of Biological Sciences* 2012;8(9):1281-1290.
- Riset Kesehatan Dasar (Riskesdas). Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI 2018.
- Riset Kesehatan Dasar (Riskesdas). Pokok-pokok hasil riset kesehatan dasar provinsi Riau. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI 2013.
- Ritschel VN, Seljeflot I, Amesen H, et al. Circulating levels of IL-6 receptor and gp130 and long-term clinical outcomes in ST-elevation myocardial infarction. *J Am Heart Assoc* 2016;5:e003014.
- Roberts R. Genetics of coronary artery disease: an update. *Methodist Debakey Cardiovasc J* 2014;10(1):7-12.
- Rose-John S. IL-6 Trans-Signaling via the soluble IL-6 receptor: Importance for the pro-inflammatory activities of IL-6. *International Journal of Biological Sciences* 2012; 8:1237-1247.
- Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease. A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. *Circulation* 2015;131:e435-e470.
- Sarwar N, Butterworth AS, et al. IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. *Lancet* 2012; 379: 1205–1213.
- Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochimica et Biophysica Acta* 2011;1813:878–888.
- Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. *Seminars in Immunology* 2014;26:2–12.

- Scheller J, Rose-John S. The interleukin 6 pathway and atherosclerosis. *The Lancet* 2012;380:388.
- Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques potential implications for inflammation and plaque instability. *Circulation* 2000;101:1372-1378.
- Schuett H, Luchtefeld M, Grothusen C, et al. How much is too much? Interleukin-6 and its signalling in atherosclerosis. *Thromb Haemost* 2009;102:215–222.
- Schuett H, Oestreich R, Waetzig GH, et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in Mice. *Arterioscler Thromb Vasc Biol* 2012;32:281-290.
- Sebba A. Tocilizumab: The first interleukin 6 receptor inhibitor. *Am J Health Syst Pharm* 2008;65(15):1413-1418.
- Senn JJ, Klover PJ, Irena A, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. *The Journal of Biological Chemistry* 2003;278:13740-13746.
- Shrivastava AK, Singh HV, Raizada A, Singh SK. C-reactive protein, inflammation and coronary heart disease. *The Egyptian Heart Journal* 2015;67:89-97.
- Stephens OW, Zhang Q, Qu P, et al. An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. *Blood* 2012;119:503-512.
- Su DF, Li ZX, Li XR, et al. Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease. *Hindawi Publishing Corporation Mediators of Inflammation* 2013. Article ID 726178, 7 pages. <http://dx.doi.org/10.1155/2013/726178>
- Swerdlow DI, Holmes MV, et al. Interleukin-6 Receptor Mendelian Randomisation Analysis C. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. *The Lancet* 2012;379:1214-1224.
- Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. *Cancer Immunol Res* 2014; 2: 288–294.

- Taqueti VR, Ridker PM. Lipid-lowering and anti-inflammatory benefits of statin therapy more than meets the plaque. *Circ Cardiovasc Imaging* 2017;10:e006676.
- Teixeira BC, Lopez AL, Macedo RCA, et al. Inflammatory markers, endothelial function and cardiovascular risk. *J Vasc Bras* 2014;13(2):108-115.
- The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet* 2010;375:132–140.
- Tomas MJS, Baluyot PM, Santos ALD, et al. Interleukin 6 as a biomarker of ischemic heart disease. *International Journal of Scientific and Research Publications* 2015;5(7):1-4.
- Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. *European Heart Journal* 2016;37:1723-1735.
- Tu Y, Fan G, Zeng T, Cai X, Kong W. Association between polymorphism within interleukin related genes and Graves' disease: a meta-analysis of 22 case-control studies. *Oncotarget* 2017;8(58):8993-9002.
- Van der Ende MY, Hartman MHT, Hagemeyer Y, et al. The LifeLines Cohort Study: Prevalence and treatment of cardiovascular disease and risk factors. *International Journal of Cardiology* 2017;228:495-500.
- Van Loon JE, de Maat MPM, Deckers JW, et al. Prognostic markers in young patients with premature coronary heart disease. *Atherosclerosis* 2012;224:213-217.
- Volpato S, Guralnik JM, Ferrucci L, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women. The Women's Health and Aging Study. *Circulation* 2001;103:947-953.
- Wainstein MV, Mossmann M, Araujo GN, et al. Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography. *Diabetol Metab Syndr* 2017;9:67. doi:10.1186/s13098-017-0266-5.
- Wang CLC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: Cardiovascular disease in diabetes mellitus atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus – mechanisms, management, and clinical considerations. *Circulation* 2016;133:2459–2502.

- Wells GL. Cardiovascular risk factors: Does sex matter? *Curr Vasc Pharmacol* 2016;14(5):452-457.
- Wolf SI, Lawson C. ICAM-1: Contribution to vascular inflammation and early atherosclerosis. In Squeri A (ed.). *Coronary artery disease – new insights and novel approaches*. Intechopen 2012:65-90.
- World Health Organization. *Global status report on noncommunicable diseases 2014. Attaining the nine global noncommunicable diseases targets, a shared responsibility*, 2014.
- Yimagou EL, Sobngwi E, Matsha TE, Kengne AP. Diabetes mellitus and inflammation. *Curr Diab Rep* 2013;13:435–444.
- Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. *BioMed Research Internasional* 2014;Article ID 698313:12 pages.
- Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004; 364: 937-952.
- Zheng GH, Chen HY, Xiong SQ. Polymorphisms of -174G>C and -572G>C in the interleukin 6 (IL-6) gene and coronary heart disease risk: A meta-analysis of 27 research studies. *PLoS ONE* 2012;7(4):e34839.
- Zhou JQ, Chen XL, Ya HD, et al. Association study between genetic polymorphism in the interleukin-6 receptor gene and coronary heart disease. *Biomed Research Internasional* 2014; Article ID 504727, 6 pages. <http://dx.doi.org/10.1155/2014/504727>
- Zou S, Pan X, Chen Z, et al. Intercellular adhesion molecule-1 K469E polymorphism and risk of coronary artery disease: a meta-analysis. *Med Sci Monit* 2014;20:2677–2682